Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CSL Ltd.

www.csl.com.au

Latest From CSL Ltd.

Coronavirus Update: Supply Chain Resilience, Trade Barriers & Drug Toxicity Risk

In addition to our daily in-depth coverage of key events relating to the coronavirus, we’re bringing you a periodic round-up of other pandemic developments. This edition covers events at the national, European and global level. 

Europe United Kingdom

GC Pharma Aiming To Outrun Rivals For COVID-19 Plasma Therapy

A South Korean pharma firm is set to soon begin pivotal clinical trials for a hyperimmune globulin for the treatment of COVID-19 patients and plans to commercialize the product this year, with a hope of outrunning rivals including Takeda.

Coronavirus COVID-19 South Korea

Glenmark To Debut Ryaltris In Australia

Glenmark ended 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.

Regulation Approvals

Year-End Cheer For Glenmark As Ryaltris To Debut In Australia

Glenmark is ending 2019 on a buoyant note, with its rhinitis therapy getting the go-ahead in Australia. Though not seen as a huge commercial opportunity in the island continent, the clearance augurs well for the product’s overall trajectory.

Australia Approvals
See All

Company Information

UsernamePublicRestriction

Register